Pelthos Therapeutics Inc. (PTHS)
Data as of , from SEC Form 4 filings.
See up to 3 months of PTHS. The 7-day demo opens the 1M and 3M ranges and puts PTHS on your watchlist.
Start 7-day demoLatest PTHS insider trades
About Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
- DURHAM, NC
- 92
- 2024
- XASE
PTHS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 2,141 | $45K |
PTHS insider transactions (Form 4)
3244 Form 4 filings on record, the earliest from Nov 15, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Richard Malamut - Director | Grant or award | Restricted Stock Units | 19,108 | - | - | |
| Richard Malamut - Director | Grant or award | Stock Option | 58,230 | - | - | |
| Scott M. Plesha - Officer | Grant or award | Restricted Stock Units | 83,678 | - | - | |
| Scott M. Plesha - Officer | Grant or award | Stock Option | 255,000 | - | - | |
| Ezra M. Friedberg - Director | Grant or award | Restricted Stock Units | 19,108 | - | - | |
| Ezra M. Friedberg - Director | Grant or award | Stock Option | 58,230 | - | - | |
| Matthew Pauls - Director | Grant or award | Restricted Stock Units | 25,478 | - | - | |
| Matthew Pauls - Director | Grant or award | Stock Option | 77,640 | - | - | |
| Knuettel Francis II - Officer | Grant or award | Restricted Stock Units | 33,472 | - | - | |
| Knuettel Francis II - Officer | Grant or award | Stock Option | 102,000 | - | - | |
| Todd C. Davis - Director | Grant or award | Restricted Stock Units | 19,108 | - | - | |
| Todd C. Davis - Director | Grant or award | Stock Option | 58,230 | - | - | |
| Peter Greenleaf - Director | Grant or award | Restricted Stock Units | 25,478 | - | - | |
| Peter Greenleaf - Director | Grant or award | Stock Option | 77,640 | - | - | |
| LIGAND PHARMACEUTICALS INC | Other | Common Stock | 1,500,000 | $10.00 | $15.00M | |
| LIGAND PHARMACEUTICALS INC | Other | Series A Convertible Preferred Stock | 15,000 | $0.00 | - | |
| LIGAND PHARMACEUTICALS INC | Other | Series A Convertible Preferred Stock | 31,279 | - | - | |
| Ezra M. Friedberg - Director | Other | Common Stock | 40,000 | $10.00 | $400K | |
| Ezra M. Friedberg - Director | Other | Common Stock | 40,000 | $10.00 | $400K | |
| Ezra M. Friedberg - Director | Open-market purchase | Series A Convertible Preferred Stock | 40,000 | $0.00 | - | |
| Ezra M. Friedberg - Director | Open-market purchase | Series A Convertible Preferred Stock | 40,000 | $0.00 | - | |
| Ezra M. Friedberg - Director | Other | Series A Convertible Preferred Stock | 40,000 | $0.00 | - | |
| Ezra M. Friedberg - Director | Other | Series A Convertible Preferred Stock | 40,000 | $0.00 | - | |
| Knuettel Francis II - Officer | Other | Common Stock | 10,000 | $10.00 | $100K | |
| Knuettel Francis II - Officer | Other | Series A Convertible Preferred Stock | 10,000 | $0.00 | - | |
| Knuettel Francis II - Officer | Other | Series A Convertible Preferred Stock | 10,000 | $0.00 | - | |
| Todd C. Davis - Director | Other | Common Stock | 1,500,000 | $10.00 | $15.00M | |
| Todd C. Davis - Director | Other | Series A Convertible Preferred Stock | 15,000 | $0.00 | - | |
| Todd C. Davis - Director | Other | Series A Convertible Preferred Stock | 31,279 | - | - | |
| Richard Malamut - Director | Grant or award | Restricted Stock Units | 24,533 | - | - | |
| Ezra M. Friedberg - Director | Grant or award | Restricted Stock Units | 24,533 | - | - | |
| Todd C. Davis - Director | Grant or award | Restricted Stock Units | 49,605 | - | - |
Recent PTHS Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
PTHS insider trading FAQ
What is the latest insider trade for PTHS?
Pelthos Therapeutics Inc. (PTHS) had 3 insider filings in the last 90 days, with the most recent on 2026-10-06. The full record for PTHS runs to 44 Form 4 filings, the earliest from 2024-11-15. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PTHS stock?
No insider purchases of PTHS were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling PTHS stock?
3 insider sales of PTHS were filed in the last 90 days, totaling $45K.
Where can I see PTHS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PTHS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Peter Greenleaf view on EDGAR
- - Ezra M. Friedberg view on EDGAR
- - Matthew Pauls view on EDGAR
- - Ezra M. Friedberg view on EDGAR
- - Matthew Pauls view on EDGAR
- - Peter Greenleaf view on EDGAR
- - Ezra M. Friedberg view on EDGAR
- - Todd C. Davis view on EDGAR
- - Knuettel Francis II view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where PTHS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PTHS with a 7-day demo
- PTHS on your watchlist
- Every PTHS Form 4 filing on record
- Up to 3 months of PTHS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
